What is PTC Therapeutics's market cap?

PTC Therapeutics (PTCT) has a market capitalization of $6.3B and trades on NASDAQ.

What is PTC Therapeutics's revenue and profitability?

PTC Therapeutics generated $827.1M in trailing twelve-month revenue with net income of $814.8M, representing a net margin of 42.3%. Gross margin stands at 96.0%, with free cash flow of $696.9M. These figures are based on the Q1 2026 filing.

Who are PTC Therapeutics's competitors?

PTC Therapeutics's key competitors include Sarepta Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Polaryx Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does PTC Therapeutics partner with?

PTC Therapeutics's notable partners include Akcea Therapeutics, Inc., Ionis Pharmaceuticals, Inc..

Where is PTC Therapeutics headquartered?

PTC Therapeutics is headquartered in United States of America and employs approximately 995 people. It has been publicly traded since 2013.

PTC Therapeutics

PTCT

PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines for rare disorders.

Market cap

$6.25B+54.9%

Revenue$827.1M-53.3%

Net income$814.8M+324%

Free cash flow$696.9M+638%

EPS (diluted)$9.38+298%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$272.6MBeat by $55.1M EPS-$0.03Beat by $0.42

Read the full report

Next report

Jul 30, 2026 (Today)

Revenue estimate$298.6M

EPS estimate$0.24

Financials

Q1 2026

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation & ratios

Valuation

See full

Market cap$6.25B+54.9%

Enterprise value$5.81B+77.1%

P/E7.7×—

P/S7.6×+5.3×

Profitability

See full

Operating margin1.6%-38.7pp

Returns & leverage

See full

Current ratio2.4×-1.5×

Segments

By product

See full

Sephience$124.6M—

Translarna$59.0M—

Emflaza$21.5M—

Other Products$11.0M—

Upstaza And Kebilidi$9.6M—

By segment

See full

Life Science$272.6M-76.8%

By geography

See full

All Other Countries Other Than Russia Brazil And United States$44.6M—

Competitors

By market cap

ALN

Alnylam Pharmaceuticals$38.5B-10.7%

Biogen$30.4B+62.0%

PTC Therapeutics$6.3B+60.1%

Sarepta Therapeutics, Inc.$1.6B+4.7%

Atrium Therapeutics $196.5M-95.5%

Tenaya Therapeutics, Inc.$164.1M+43.2%

Polaryx Therapeutics, Inc. $99.2M—

Gain Therapeutics$73.8M+36.0%

By revenue growth

ALN

Alnylam Pharmaceuticals+82.6%

Sarepta Therapeutics, Inc.+9.9%

Biogen+0.3%

PTC Therapeutics-53.3%

By net margin

PTC Therapeutics42.25%+119pp

ALN

Alnylam Pharmaceuticals11.72%+21.5pp

Biogen8.81%-6.5pp

Sarepta Therapeutics, Inc.4.64%-38.4pp

Profile

PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines for rare disorders. The company leverages a specialized scientific platform and global commercial infrastructure to address high unmet medical needs in neurology and metabolism. Its core value proposition lies in advancing a diversified pipeline of transformative therapies, including gene therapies and small molecule treatments, for both pediatric and adult populations.

Competitive position

A leading player in the rare disease space with a first-of-its-kind gene therapy for AADC deficiency and a significant commercial presence in the DMD market.

GeographiesUnited States, European Economic Area, Brazil, Japan, Latin America

Customer segmentsSpecialized Healthcare Providers, Rare Disease Patients, Government Health Authorities

Business modelResearch and Development, Direct Product Sales, Licensing and Collaboration

SuppliersGenetic sequencing providers, Specialized contract manufacturing organizations, Clinical research organizations, Raw material suppliers for gene therapy

CustomersSpecialty pharmacies, Hospitals, Government healthcare systems, Private insurance payers

CountryUnited States of America

Listed2013

Employees995.0

CEOMatthew Klein

SectorHealthcare

IndustryBiotechnology

Websiteptcbio.com

FilingsSEC EDGAR

Ask your AI about PTC Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's market cap?: PTC Therapeutics (PTCT) has a market capitalization of $6.3B and trades on NASDAQ.
What is PTC Therapeutics's revenue and profitability?: PTC Therapeutics generated $827.1M in trailing twelve-month revenue with net income of $814.8M, representing a net margin of 42.3%. Gross margin stands at 96.0%, with free cash flow of $696.9M. These figures are based on the Q1 2026 filing.
Who are PTC Therapeutics's competitors?: PTC Therapeutics's key competitors include Sarepta Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Polaryx Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does PTC Therapeutics partner with?: PTC Therapeutics's notable partners include Akcea Therapeutics, Inc., Ionis Pharmaceuticals, Inc..
Where is PTC Therapeutics headquartered?: PTC Therapeutics is headquartered in United States of America and employs approximately 995 people. It has been publicly traded since 2013.